Posted by Michael Wonder on 13 Dec 2021
InterVene’s BlueLeaf Endovenous Valve Formation System granted breakthrough device designation by the FDA
13 December 2021 - InterVene announced today that it has received breakthrough device designation by the FDA for the company’s BlueLeaf Endovenous Valve Formation System.
BlueLeaf is the first catheter-based solution developed for deep vein reflux -- the failure of venous valves in the legs -- which does not require an implant.
